Equities

SymBio Pharmaceuticals Ltd

SymBio Pharmaceuticals Ltd

Actions
  • Price (USD)1.21
  • Today's Change0.00 / 0.00%
  • Shares traded100.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 20 2024 14:42 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SymBio Pharmaceuticals Limited is a Japan-based pharmaceutical company. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The Company develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The Company manufactures and sells medicines through domestic and foreign pharmaceutical companies. The Company's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.

  • Revenue in USD (TTM)30.20m
  • Net income in USD-17.85m
  • Incorporated2005
  • Employees109.00
  • Location
    SymBio Pharmaceuticals LtdToranomon 30 Mori Bldg.3-2-2, ToranomonMINATO-KU 105-0001JapanJPN
  • Phone+81 354721125
  • Fax+81 354723054
  • Websitehttps://www.symbiopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CEL-SCI Corp0.00-29.95m70.95m43.00--4.95-----0.6304-0.63040.000.26450.00-------87.78-70.19-103.56-78.31-------15,434.151.18-39.260.4319------13.99--223.59--
Eagle Pharmaceuticals Inc257.55m11.95m74.29m134.006.280.29722.270.28840.9110.91119.5919.250.65491.552.561,922,022.003.046.374.047.9869.8471.864.647.851.673.550.21780.0084.565.99513.14-8.42-49.05--
Journey Medical Corp80.00m-4.16m76.51m58.00--8.40--0.9564-0.3095-0.30954.130.64980.9852.274.281,379,276.00-5.12---17.85--66.22---5.20--0.93570.40490.5773--7.48--87.00------
Marinus Pharmaceuticals Inc28.29m-145.34m78.56m165.00------2.78-2.64-2.640.5142-0.29920.15540.85363.72171,442.40-79.82-49.64-96.93-57.7691.22---513.80-518.962.93-13.621.29--21.63---613.59--7.47--
Eyenovia Inc8.78k-32.44m79.15m57.00--37.54--9,014.29-0.7448-0.74480.00020.03840.0003--0.008154.04-116.94-80.31-190.14-117.700.00---369,519.70-680.950.6645-16.030.8914------2.68--152.20--
SCYNEXIS Inc140.39m101.33m79.72m29.001.051.08--0.56782.012.012.891.961.49--136.304,840,862.00107.48-30.02175.37-36.3588.97--72.18-86.76--193.810.1433--2,652.72252.64206.74------
Cellectar Biosciences Inc0.00-50.98m82.09m20.00--8.36-----3.17-3.170.000.7890.00----0.00-176.58-83.69-295.36-99.80-----------4.810.00-------32.80--17.55--
Zhong Yuan Bio-Technology Holdings Ltd2.49m232.02k88.22m35.00391.37348.44--35.380.0128-0.01760.13950.01430.8583-1.613.2571,253.436.49--19.10--106.30--7.57--0.83092.530.8593---28.60---148.37------
CASI Pharmaceuticals Inc28.94m-30.48m88.45m176.00--5.72--3.06-2.28-2.282.161.150.39541.003.41164,437.50-40.88-34.75-59.15-46.9158.3655.98-103.40-153.723.25-76.700.5458---21.41--34.27--14.65--
SymBio Pharmaceuticals Ltd - ADR30.20m-17.85m90.37m109.00--1.19--2.99-0.4351-0.43510.74031.020.54392.765.14277,089.10-32.15---35.33--78.38---59.12--10.43--0.00---44.15---266.45------
Eton Pharmaceuticals Inc34.30m913.00k91.97m30.00105.825.9449.632.680.03380.03381.330.60311.258.419.641,143,467.003.34-46.225.72-58.2066.2472.162.66-76.861.43--0.2447--48.90--89.62--26.85--
Elutia Inc25.05m-49.46m92.04m54.00------3.67-2.35-2.341.24-2.070.52192.064.27463,833.30-103.05-42.93-599.50-79.3442.0143.32-197.48-64.160.5499-1.36-----49.69-8.71-25.39--12.74--
LifeVantage Corp205.45m3.60m101.86m248.0028.693.8014.000.49580.27960.279616.012.113.202.5391.56828,443.605.6011.658.5118.9279.3282.201.753.421.01--0.005.233.410.9838-18.59-18.77-7.98--
Data as of May 20 2024. Currency figures normalised to SymBio Pharmaceuticals Ltd's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.